Thank you for subscribing!

The Paradigm Shifting AI Technology Transforming a $40B Industry

How NetraMark’s Business Could Completely Alter the Clinical Trial Landscape

NetraMark (CSE : AIAI, OTC: AINMF, FRA: 8TV) is an AI software technology company dedicated to improving the understanding and efficacy of how clinical trial data relates to pharmaceutical candidates.

Its products help optimize the path to new drug development by using a pharmaceutical company’s data to help define the biomarkers associated with clinical trial participants that have an increased chance of being a positive responder to a candidate medicine.  The NetraMark technology will ultimately drive the key clinical trial enrichment criteria to be used in the recruitment of participants for the trial.

There is a big opportunity in this industry, as only 12% of pharmaceutical candidates make it through the clinical  trial process. For an industry worth roughly $40B worldwide, the ability to increase the likelihood of a new drug making it past the (costly) later stages of testing translates into a HIGH VALUE business.

Key Investment Factors

Big Market Opportunity – The global market size for clinical trials and R+D expenditures is $40B+. That represents a large opportunity for an effective way to increase the likelihood of a successful clinical trial. With less than 12% of trials making it to FDA approval, NetraMark has a real chance to make a name for itself. 

Large Valuation Multiples –  It isn’t unheard of for companies in the AI pharmaceutical space to hit valuation multiples of 20X-30X (sometimes more). NetraMark is projecting $2.8M by September of 2023 and $7.9M for its 2024 Fiscal year. If that trend continues, this could prove to be a valuable investment, on valuation alone. 

Experienced Team – NetraMark’s team is stacked. From highly accomplished and respected scientists and doctors, like Dr. Joseph Geraci who was recognized for research on placebo response related to mental health, to Josh Spiegel, who helped engineer a $330M exit in a recent deal. The guidance and expertise we see on their board is encouraging.

Effective Technology – None of this matters if the technology doesn’t work, and after 5 years of development, the NetraMark AI system (NetraAI) WORKS. The AI software has the ability to use small data sets to make significant observations and connections that help trials proceed.


Using AI to Make BIG Insights Out of Small Data Sets

With less than 12% of trial candidates making it through to FDA approval, wasting millions of dollars and years of research, a shift in the industry is sorely needed.

NetraMark is on a mission to change the way clinical trials go, by utilizing a revolutionary AI and Machine Learning software. NetraAI has the ability to take the small data sets that normally limit the ability to find significance, and use advanced models to uncover insights that traditional review just can’t. 

This change in clinical trials could result in saving pharmaceutical companies large sums of money, while propelling research that could save even more lives. It’s a win-win. 

NetraMark’s advanced machine learning techniques aim to revolutionize traditional drug development by providing a deeper understanding of diseases and their mechanisms. This leads to more effective clinical trial designs, increased efficacy, and reduced costs due to fewer failures. By saving money and increasing the likelihood of success, NetraMark will become invaluable to the pharmaceutical trial process. 

Its disease and symptom-specific models allow NetraMark to identify the most suitable patients for clinical trials with greater accuracy. This results in more confidence in smaller population sizes and reduces the chances of poor outcomes and wasted resources for pharmaceutical companies. The majority of trials are run with fewer than 1,000 participants, meaning the data sets can be small. NetraAI can draw statistically significant conclusions with even these smaller sample sizes, leading to a greater chance of a successful trial. 


Cumulative # of trials by anticipated # participants (1999-2021)*


Dr. Joseph Geraci, Co-Founder of NetraMark, has been recognized for his research on the placebo response, and NetraMark has designed its product to take such response into account. Its NetraAI technology keeps clients ahead of the competition by predicting placebo responder characteristics with greater accuracy. Those who do use NetraMark have an advantage over the standard practice, making it a valuable tool in the space. 

NetraMark’s technology can turn disparate and irregular data into uniformed datasets, allowing clients to uncover new insights about patient relationships and empowering their data science teams. In one white paper regarding genes associated with pancreatic cancer, traditional science uncovered one gene, while NetraAI was able to map out an entire network of potential genes that when overly expressed were associated with positive responders. This is game-changing technology. 


Press Releases





NetraMark is well positioned to grow over the next few years at a decent clip. We’ve seen the stock move from 0.1 to 0.3 from 1/11/23 – 2/10/23, and are confident to see more movement as the company starts really doing business and getting clients results. NetraMark is projecting $2.8M by September of 2023 and $7.9M by the next year, and if the company’s valuation stays on track with industry standards, that would drive a meaningful increase to the company valuation in just two years. 

This is an exciting company in an industry that needs a shift. AI pharmaceutical companies are on our watchlist anyway, and this is one we’re going to keep a close eye on.



George Achilleos

George is a seasoned Business Executive with 25+ years of experience, who began in the technology sector at IBM. He has led over $50M of business deals and transactions and has generated over $70M+ of revenue in his career. He has been in senior executive positions in the Digital Strategy, ECommerce, Nano Technology and Retail industries and has served in advisor board roles in the media, clean energy and plant-based foods sectors. He holds a Bachelor of Commerce from The University of Calgary.


Josh Spiegel

25-plus years of experience in finance, sales and corporate strategy, with a strong background in health care, business services and technology. Prior to joining NetraMark, Mr. Spiegel was the vice-president of business strategy at VeraSci, where he leveraged his experience to provide strategic planning and oversight of commercial operations, including the launch of the Pathway eClinical platform and positioned the company for a highly successful $330-million (U.S.) exit to WCG Clinical, a leader in the pharmaceutical services sector.


Dr. Joseph Geraci
Chief Technology Officer / Chief Scientific Officer and Director

Co-Founder of NetraMark, mathematician, medical scientist, and quantum machine learning specialist with postdocs in machine learning, oncology and neuropsychiatry. He is associated with the department of Molecular Medicine and Pathology at Queen’s University in Ontario, Canada, and the Centre for Biotechnology and Genomics Medicine Medical College of Georgia, USA.


Dr. Luca Pani
Chief Innovation and Regulatory Officer

Dr. Pani is an academic both at the University of Miami in the United States and in Modena, Italy, and the former director-general of the Italian Medicines Agency (AIFA) (2011 to 2016), where he managed a multibillion-dollar budget for drug expenditures and negotiations on behalf of the Italian national health system. Dr. Pani was the vice-president for regulatory strategy and market access innovation at VeraSci, where, among other matters, provided scientific strategic planning on the FDA (U.S. Food and Drug Administration) qualification program for the Pathway eClinical platform. This supported the company for a highly successful $330- million (U.S.) exit to WCG Clinical, a leader in the pharmaceutical services sector.


Dr. D.J. Cook
Chief Medical Officer

D.J. Cook MD, PhD is a neurosurgeon and neuroscientist at Queen’s University where he is division head and chair of neurosurgery. Dr. Cook completed his MD, PhD and residency at the University of Toronto and undertook fellowship training at Stanford University in Cerebrovascular and Skull Base Surgery. Dr. Cook’s present research is focused on the development of predictive imaging, physiological and behavioral biomarkers in stroke and traumatic brain injury. His work includes the use of multi-sequence MRI analysis using artificial intelligence algorithms to derive novel insights into mechanisms of disease and to monitor recovery and therapy.


Swapan Kakumanu

Mr. Kakumanu brings over 25 years of senior finance and operations experience. He has served at senior executive management levels, both in public and private companies in high growth technology, blockchain, manufacturing, trading and oil field services industries. He has held senior management roles as president, chief executive officer and chief financial officer, where he has played a key role in raising over $200-million through various financing vehicles, including debt, convertible debt, equity and other non-dilutive instruments both in the private and public markets. 

Disclaimer language

Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Nurosene Health Inc. (MEND.CN)
  • Amount & Form of Compensation - $600,000.00 in Common Stock
  • Who Paid for the Campaign & Position with Company if any - Nurosene Health Inc. (MEND.CN)
  • Period of Campaign - 7/1/2021 - 7/1/2022
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - Nurosene Health Inc. (MEND.CN)
  • Number of Shares We or our Affiliates Hold - 284,360
  • Price We Paid Per Share - $0
  • Date Issued - 06/30/2021
The information set out above is based on a number of assumptions including that the Company will hold an average of twenty four (24) prospect meetings per quarter, an expected average time to close of six (6) months, the average conversion rate of twenty percent (20%), average revenue per contract between $75,000 CDN and $400,000 CDN (depending on scope of work) and to be paid, on average, within thirty (30) to ninety (90) days of milestone completion - See “Cautionary Note Regarding Forward-Looking Information and Forward-Looking Statements”, “Cautionary Note Regarding Future-Oriented Financial Information” and “Risk Factors” above. “Contracted Value” equals revenue payable under contracts for services with customers that we have executed other than revenue recognized under IFRS during the applicable period. Contracted Value is subject to our clients’ completion of necessary milestones under their research and clinical trial programs so it may not be recognized for many months or at all. The Company does not expect the Projected Contracted Values set out above to be converted to recognized revenue within the fiscal year. There can be no assurance that Contracted Value will be recognized or received when estimated or at all. Contracted Value is a non-IFRS measure. It does not have a standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers. The most directly comparable financial measure to Contracted Value in the financial statements of the Company is revenue. Contracted Value is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Management believes that Contracted Value is useful as a supplement to comparable IFRS financial information. Management reviews this metric on a regular basis and uses it, together with financial measures included in the Company’s financial statements, to evaluate and manage the performance of the Company and to account for the value of a contract entered into, but not completed.

Related Post

Register to Download the Presentation

Go to website
Go to top